The Implications of Actovegin® in Sport: A Brief Review
References
- Stelmakh A, Abrahamovych O, Cherkas A. Highly purified calf hemodialysate (Actovegin®) may improve endothelial function by activation of proteasomes: A hypothesis explaining the possible mechanisms of action. Med Hypotheses. 2016;95:77-81.
- Machicao F, Muresanu DF, Hundsberger H, Pflüger M, Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci. 2012;322(1-2):222-7.
- Somogyi E, Sotonyi P, Nemes A. The effects of a deproteinized blood extract on the myocardial changes developing during experimentally induced intermittent hypoxia. Arzneimittel-forschung. 1979;29(9):1376-81.
- Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. Actovegin®: a biological drug for more than 5 decades. Wien Med Wochenschr. 2011;161(3-4):80-8.
- Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479-84.
- Jonathan V. Affidavit of Jonathan Vaughters. New York, USA: United States Anti-Doping Agency; 2012. [Available from: https://www.usada.org/wp-content/uploads/Vaughters-Jonathan-Affidavit.pdf]
- World Anti-Doping Agency. Coordinating Investigations and Sharing Anti-Doping Information and Evidence. Montréal: World Anti-Doping Agency; 2011. [Available from: https://www.wada-ama.org/sites/default/files/resources/files/WADA_Investigations_Guidelines_May2011_EN.pdf]
- Geistlinger M, Subiotto R, Schimke M. CAS 2016/A/4708 Belarus Canoe Association & Belarusian Senior Men’s Canoe and Kayak team members v. International Canoe Federation (ICF). Lausanne, Switzerland: Court of Arbitration for Sport; 2017. [Available from: https://www.sennferrero.com/descargaspdf/tascas/201704/4708.pdf]
- Duval A, Rigozzi A, editors. Yearbook of International Sports Arbitration 2017: Asser Press by Springer; 2017.
- Haas U, Bernasconi M, Subiotto R. Arbitration CAS 2017/A/5045 Maria Farnosova v. International Association of Athletics Federations (IAAF) & All Russia Athletics Federation (ARAF), award of 27 July 2018. Lausanne, Switzerland: Court of Arbitration for Sport; 2018. [Available from: https://jurisprudence.tascas.org/Shared%20Documents/5045.pdf]
- Lee P, Rattenberry A, Connelly S, Nokes L. Our experience on Actovegin, is it cutting edge? Int J Sports Med. 2011:237-41.
- Maillo L. Anaphylactic shock with multiorgan failure in a cyclist after intravenous administration of Actovegin. Ann Intern Med. 2008;148(5):407.
- Lee P, Kwan A, Nokes L. Actovegin®-Cutting-edge Sports Medicine or" Voodoo" Remedy? Curr Sports Med Rep. 2011;10(4):186-90.
- Lee P, Nokes L, Smith P. No effect of intravenous Actovegin ® on peak aerobic capacity. Int J Sports Med. 2012:305-9.
- Søndergård SD, Dela F, Helge JW, Larsen S. Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle. Eur J Sport Sci. 2016;16(7):801-7.
- Brock J, Golding D, Smith PM, Nokes L, Kwan A, Lee PY. Update on the role of Actovegin in musculoskeletal medicine: a review of the past 10 years. Clin J Sport Med. 2020;30(1):83-90.
Language: English
Submitted on: Nov 26, 2023
Accepted on: Dec 19, 2023
Published on: Mar 23, 2024
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2024 Dragana Milovanovic, Emilija Stojanovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.